A clinical trial for the potential cancer drug NGR-hTNF will move into a Phase III stag in 40 centers worldwide, including in the United States. Results will be available in 2013.
Related Post:
Mesothelioma Clinical Trial in Italy Tests the Use of NGR-hTNF
In a recent press release issued by MolMed S.p.A., an Italian biotechnology company, a Phase III clinical trial for malignant pleural mesothelioma patients has begun ...
Phase II Clinical Trial Set to Begin for Mesothelioma Patients
The Australian drug discovery and development company Bionomics has plans to begin a Phase II clinical trial using the disrupting agent BNC105 in mesothelioma patients. ...
Mesothelioma Clinical Trials are Making Headway in the Search for a Cure
Mesothelioma is an aggressive form of asbestos-related cancer with an extremely low survival rate. Every year cancer researchers and doctors around the country perform a ...
Mesothelioma Treatment Phase II Clinical Trial Offers Hope
The biotechnology company MolMed, based in Italy, has announced positive results for their Phase II trial of NGR-hTNF for the treatment of malignant pleural mesothelioma. ...
Merck Mesothelioma Drug Zolinza Fails in Phase III of Clinical Trial
An experimental chemotherapy treatment being investigated for benefits to pleural mesothelioma patients recently failed a Phase III trial after not achieving the required clinical significance. ...
Tags: Asbestos, asbestos cancer articles, asbestos exposure, lung cancer, Malignant Mesothelioma, mesothelioma, mesothelioma and asbestos cancer, mesothelioma articles, mesothelioma cancer, treatment